These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25256217)

  • 1. PKCβ positively regulates RANKL-induced osteoclastogenesis by inactivating GSK-3β.
    Shin J; Jang H; Lin J; Lee SY
    Mol Cells; 2014 Oct; 37(10):747-52. PubMed ID: 25256217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of glycogen synthase kinase-3β is required for osteoclast differentiation.
    Jang HD; Shin JH; Park DR; Hong JH; Yoon K; Ko R; Ko CY; Kim HS; Jeong D; Kim N; Lee SY
    J Biol Chem; 2011 Nov; 286(45):39043-50. PubMed ID: 21949120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide.
    Koide N; Kaneda A; Yokochi T; Umezawa K
    Int Immunopharmacol; 2015 Mar; 25(1):162-8. PubMed ID: 25617668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN regulation by the Akt/GSK-3β axis during RANKL signaling.
    Jang HD; Noh JY; Shin JH; Lin JJ; Lee SY
    Bone; 2013 Jul; 55(1):126-31. PubMed ID: 23419777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
    Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
    Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
    Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
    J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-κB and NFAT activity.
    Yao J; Li J; Zhou L; Cheng J; Chim SM; Zhang G; Quinn JM; Tickner J; Zhao J; Xu J
    J Cell Physiol; 2015 Jun; 230(6):1235-42. PubMed ID: 25363829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
    Kim EC; Park J; Noh G; Park SJ; Noh K; Kwon IK; Ahn SJ
    Bioelectromagnetics; 2018 Jul; 39(5):394-404. PubMed ID: 29709064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts.
    Komarova SV; Pereverzev A; Shum JW; Sims SM; Dixon SJ
    Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2643-8. PubMed ID: 15695591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen- and stress-activated protein kinase 1 activates osteoclastogenesis in vitro and affects bone destruction in vivo.
    Ha J; Kim HJ; Huang H; Lee ZH; Kim HH
    J Mol Med (Berl); 2013 Aug; 91(8):977-87. PubMed ID: 23619911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
    Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
    Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
    Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
    Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
    Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
    J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotropein Protects against Inflammatory Bone Loss and Suppresses Osteoclast Formation and Bone Resorption by Inhibiting NFATc1 via NF-κB and Akt/GSK-3β Pathway.
    Zhang Q; Hu S; He Y; Song Z; Shen Y; Zhao Z; Zhang Q; Qin L; Zhang Q
    Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
    Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
    Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.